All Articles

BYNordic Acquisition Corp. continues its hunt for a Northern European tech target, extending its deadline as the SPAC market evolves. Is this a sign of struggle or strategic patience?

Late-stage trial data suggests Capricor Therapeutics' Deramiocel could address a critical unmet need in Duchenne muscular dystrophy – heart failure. But funding and market access remain key challenges.

Mills Wealth Advisors hosts a free webinar addressing key changes to retirement planning, including updated IRS limits and the impact of the SECURE 2.0 Act. Experts offer insights into navigating the evolving financial landscape.

Clinical-stage biotech Perspective Therapeutics reported a Q3 loss as it invests heavily in radiopharmaceutical research, but maintains a healthy cash position and promising data for hematologic malignancy treatments.

Kaltura’s acquisition of eSelf.ai aims to revolutionize video engagement with lifelike, interactive avatars. But can the company overcome recent financial headwinds to capitalize on this tech?

Novartis’ acquisition of Avidity Biosciences signals a new era in RNA therapeutics, with a focus on delivering targeted therapies for muscular dystrophies and other genetic diseases. The deal includes a planned spin-off for cardio programs.

Oculis Biotech, a clinical-stage biopharmaceutical company, has raised nearly $300 million to accelerate development of innovative therapies for debilitating eye diseases, including optic neuritis and dry eye disease.

Former Energy Secretary Rick Perry's firm plans a massive private grid in Texas to fuel the next generation of AI, but the scale of the project raises questions about feasibility and sustainability.

Cancer diagnostics firm Insight Molecular is aggressively expanding through acquisitions, fueling growth but also creating accounting complexities and short-term losses. Analysts question if the strategy will deliver long-term value.

Strong YUPELRI sales drive Theravance Biopharma's Q3 gains, but rising competition and evolving treatment options in the COPD market demand strategic adaptation.

FibroGen has restructured its operations with the sale of its China business, bolstering its cash runway and refocusing on advancing key clinical programs like FG-3246 and roxadustat. A closer look at the company's new direction.

Cellar Beast Winehouse blends exquisite food & wine experiences with a commitment to community & a powerful story of veteran ownership, boosting Pennsylvania’s growing wine region.

Canadian brokerage KIC Realty is giving its agents access to AI-powered marketing platform Roomvu, aiming to streamline content creation and give them a competitive edge. Is this the future of real estate marketing?

A new K-6 math curriculum, deeply rooted in decades of research and aligned with California’s evolving educational framework, has been approved for statewide use. Will it reshape how the Golden State teaches math?

Riviana’s ‘Jars of Hope’ campaign isn’t just donating rice; it’s building a model for sustainable giving & tackling hunger in California with a unique buy-one-give-one approach.

Guaranteed Rate Affinity’s new team, led by VP Sabina Adamski, aims to redefine the mortgage experience in Southern California with a focus on personalized service and integrated real estate solutions. Is this the future of homebuying?

Ferrara’s BRACH’S is launching a dedicated candy cane opener – a surprisingly targeted solution to a minor, yet pervasive, holiday headache. Is this clever marketing, genuine innovation, or a glimpse into a future of hyper-personalized products?

The Africa Tech Festival is set to gather industry leaders, policymakers & innovators to discuss the continent’s booming tech scene and the strategies needed to fuel sustainable growth.

Amsterdam Nursing Home earns top marks in Newsweek's 'America's Best' list. We explore how a focus on data-driven care, staff empowerment, and resident well-being sets this NYC facility apart in a competitive market.

Ontario regulators have issued an order against Adam Arquette and his firm, alleging unregistered trading, fraud, and the mismanagement of over $100M in investor funds. A deeper look at the case and its implications.